DUBLIN – Investors in Molecular Partners AG received a much-needed boost Wednesday as the company entered an immuno-oncology collaboration with Amgen to develop its preclinical multispecific Darpin molecule MP0310, in return for $50 million up front and up to $497 million in development, regulatory and commercial milestones, plus tiered double-digit royalties on product sales.